Compare · BNTX vs IMVT
BNTX vs IMVT
Side-by-side comparison of BioNTech SE (BNTX) and Immunovant Inc. (IMVT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and IMVT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $21.65B, about 3.4x IMVT ($6.40B).
- Over the past year, BNTX is down 16.8% and IMVT is up 98.2% - IMVT leads by 115.0 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- BioNTech SE
- Immunovant Inc.
- Price
- $87.79+1.87%
- $32.03+2.69%
- Market cap
- $21.65B
- $6.40B
- 1M return
- -6.29%
- +11.84%
- 1Y return
- -16.76%
- +98.21%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2019
- News (4w)
- 8
- 8
- Recent ratings
- 25
- 25
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Immunovant Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
- SEC Form 6-K filed by BioNTech SE
- Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
- BioNTech upgraded by UBS with a new price target
- Bernstein initiated coverage on BioNTech with a new price target
- SEC Form 6-K filed by BioNTech SE
- BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
- SEC Form 6-K filed by BioNTech SE
- BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
Latest IMVT
- Director Fromkin Andrew J. exercised 196,601 shares at a strike of $8.22 and sold $7,438,111 worth of shares (221,951 units at $33.51), decreasing direct ownership by 25% to 74,382 units (SEC Form 4)
- SEC Form 144 filed by Immunovant Inc.
- Chief Operating Officer Gloria Melanie sold $101,072 worth of shares (3,115 units at $32.45), decreasing direct ownership by 1% to 242,107 units (SEC Form 4) to satisfy withholding obligation
- Director Pande Atul exercised 6,000 shares at a strike of $8.43 and sold $192,000 worth of shares (6,000 units at $32.00) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Immunovant Inc.
- SEC Form 10-K filed by Immunovant Inc.
- Immunovant Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
- Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
- Director Susman Robert Graham sold $67,979 worth of shares (2,502 units at $27.17) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 36,394 units (SEC Form 4)